Neurelis Raises Series B Funding For Epilepsy Treatment

San Diego-based Neurelis, a developer of a drug treatment for epilepsy, has raised a Series B round of funding, the company said this morning. Size of that funding was not announced. The funding was led by HBM Healthcare Investments, and also includes earlier investor LYZZ Capital. According to Neurelis, the funding will go towards clinical trials of its intranasal drug aimed at treating pediatric, adolescent, and adult epilepsy patients who experience acute repetitive or cluster seizures. The company said it currently is targeting an NDA application for submission in 2018. Craig C. Chambliss is President and Chief Executive Officer of Neurelis.